Organization | The Leona M. and Harry B. Helmsley Charitable Trust

The Leona M. and Harry B. Helmsley Charitable Trust Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4

Founded: New York City New York United States (1999)

Organization Overview

First Clinical Trial

2010

NCT01106157

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

The Leona M. and Harry B. Helmsley Charitable Trust

Active Ingredients

Drugs in Phase 4 Trials (4)

infliximab (remicade) (1 trial)

insulin aspart (Novolog) (1 trial)

insulin glargine (toujeo) (1 trial)

insulin human (humulin) (3 trials)

Drugs in Phase 3 Trials (2)

fenofibrate (fenoglide) (1 trial)

naltrexone (revia) (1 trial)

Drugs in Phase 2 Trials (5)

acetazolamide (diamox) (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (2 trials)

dapagliflozin (farxiga) (1 trial)

Filgrastim (neupogen) (1 trial)

sargramostim (leukine) (1 trial)

Drugs in Phase 1 Trials (2)

insulin lispro (humalog) (1 trial)

mas-1 adjuvanted insulin b-chain (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Crohn Disease (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Hypoglycemia (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 13